{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:53Z","timestamp":1792719893060,"version":"4.5.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Many recent studies began to explore the therapeutic potential of FAP-targeted radionuclide therapy for refractory cancers. In this case, we presented the experience of multiple cycles of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-46 radionuclide therapy in a 34-year-old man with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). Intense radiotracer uptake was observed in RAIR-DTC metastatic lesions on the pretreatment\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAPI PET\/CT and posttherapeutic scintigraphy. Follow-up examinations after 4 cycles of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-46 treatment revealed stable metastatic lesions, resulting in stable disease. This case demonstrated the potential feasibility of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-46 in the treatment of advanced RAIR-DTC; further research on improving the FAP-targeting vector may be necessary.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000004260","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T09:56:47Z","timestamp":1651226207000},"page":"906-907","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":47,"title":["FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177Lu-FAPI-46"],"prefix":"10.1097","volume":"47","author":[{"given":"Hao","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"bib1-20250621","article-title":"Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/RLU.0000000000003730","article-title":"68Ga-FAPI PET\/CT versus 18F-FDG PET\/CT for detecting metastatic lesions in a case of radioiodine-refractory differentiated thyroid cancer","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RLU.0000000000003569","article-title":"68Ga-FAPI PET\/CT in thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","article-title":"177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/RLU.0000000000003842","article-title":"Two tumors, one target: preliminary experience with 90Y-FAPI therapy in a patient with metastasized breast and colorectal cancer","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein Inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","article-title":"Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients","year":"2021","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:04:35Z","timestamp":1750521875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004260","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}